<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04301609</url>
  </required_header>
  <id_info>
    <org_study_id>PR(AG)447/2019</org_study_id>
    <nct_id>NCT04301609</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Assess the Improvement of Fatigue, Sleep Problems, Anxiety / Depression, Neurovegetatives Alterations and Quality of Life After the Administration of ImmunoVita® in Chronic Fatigue Syndrome Patients</brief_title>
  <official_title>Randomized, Comparative, Double-blind, and Placebo-controlled Clinical Trial to Assess the Improvement of Fatigue, Sleep, Anxiety / Depression, Neurovegetatives Alterations and Quality of Life After the Administration of ImmunoVita® in Chronic Fatigue Syndrome Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vitae Health Innovation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Vall d'Hebron</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vitae Health Innovation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic Fatigue Syndrome, also known as Myalgic Encephalomyelitis (CFS / MS) is a medical&#xD;
      entity characterized mainly by debilitating and prolonged fatigue lasting more than 6 months,&#xD;
      post-exertion fatigue (physical and / or mental), non-sleep restorative, cognitive impairment&#xD;
      and orthostatic intolerance with prolonged recovery that is not relieved by rest. Currently,&#xD;
      the etiopathogenic mechanisms of the disease are not known, although mitochondrial&#xD;
      dysfunction with bioenergetic immuno-metabolism alterations, oxidative stress, and&#xD;
      immuno-inflammatory response stands out. At present, there is no diagnostic test, nor&#xD;
      effective treatment in the disease. ImmunoVita, is a food supplement composed of the latest&#xD;
      yeast beta-glucans, in addition to vitamin D3, vitamin B6 and zinc, which could contribute to&#xD;
      the normal functioning of the immune system and the inflammatory response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with CFS / ME, neuroimmune, gastrointestinal, autonomic and cardiovascular&#xD;
      alterations have been observed, among others. CFS / ME is characterized by disabling chronic&#xD;
      fatigue, non-restorative sleep, severe intolerance to physical exercise, neurocognitive&#xD;
      dysfunction with changes in concentration and immediate memory and neurovegetative symptoms&#xD;
      in the form of dizziness, syncopes and alterations in bowel and bladder rhythm . Within the&#xD;
      etiopathogenic hypotheses of the disease, they are involved if patients treated with&#xD;
      ImmunoVita® could significantly reduce the scores on the scale of the impact of fatigue,&#xD;
      sleep problems, neurovegetative dysfunction, anxiety / depression, and improve the quality of&#xD;
      life compared to the placebo group.&#xD;
&#xD;
      Based on the different etiopathogenic hypotheses of the syndrome, various mechanisms would be&#xD;
      involved, which could modulate them, the ImmunoVita food complex.&#xD;
&#xD;
        1. Do patients with CFS / ME have high scores on the fatigue impact scale, hospital&#xD;
           anxiety-depression scale and Pittsburg sleep quality questionnaire?&#xD;
&#xD;
        2. Do patients with CFS / ME have high scores in the autonomic dysfunction symptomatology&#xD;
           scale?&#xD;
&#xD;
        3. Do patients with CFS / ME have low scores in the SF-36 quality of life questionnaire?&#xD;
&#xD;
        4. Do CFS / MS patients treated with ImmunoVita significantly reduce the scores on the&#xD;
           scales of fatigue, anxiety / depression and autonomic dysfunction?&#xD;
&#xD;
        5. Will patients with CFS / ME treated with ImmunoVita significantly increase the scores on&#xD;
           the SF-36 quality of life questionnaire?&#xD;
&#xD;
      GOALS&#xD;
&#xD;
      Main goal&#xD;
&#xD;
      The objective of this study is to assess the efficacy of active ImmunoVita® in patients with&#xD;
      CFS / MS vs. placebo in the perception of fatigue, evaluated through the scale of perception&#xD;
      of fatigue (FIS-40).&#xD;
&#xD;
      Secondary goals:&#xD;
&#xD;
        1. Analyze the efficacy of active ImmunoVita®, in patients with CFS / ME vs. placebo in the&#xD;
           improvement of neurovegetative dysfunction, through the COMPASS 31 questionnaire.&#xD;
&#xD;
        2. Evaluate the efficacy of active ImmunoVita® in patients with CFS / MS vs. placebo in the&#xD;
           improvement of sleep dysfunction, through the Pittsburg questionnaire.&#xD;
&#xD;
        3. Analyze the efficacy of active ImmunoVita®, in patients with CFS / ME vs. placebo in the&#xD;
           improvement of anxiety-depressive symptomatology, through the hospital&#xD;
           anxiety-depression scale (HAD).&#xD;
&#xD;
        4. Evaluate the efficacy of active ImmunoVita®, in patients with CFS / ME vs. placebo in&#xD;
           the improvement of the quality of life, through the SF-36 questionnaire.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 16, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 16, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Perception of fatigue (FIS-40).</measure>
    <time_frame>9 months</time_frame>
    <description>The objective of this study is to assess the efficacy of active ImmunoVita® in patients with CFS vs. placebo in the perception of fatigue, evaluated through the scale of perception of fatigue (FIS-40).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurovegetative alterations (COMPASS 31)</measure>
    <time_frame>9 months</time_frame>
    <description>To analyze the efficacy of the active product, in patients with CFS / ME versus placebo in the improvement of neurovegetative dysfunction, through the COMPASS 31 questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep dysfunction (Pittsburg questionnaire)</measure>
    <time_frame>9 months</time_frame>
    <description>To evaluate the efficacy of the active product, in patients with CFS / ME vs. placebo in the improvement of sleep dysfunction, through the Pittsburg questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital anxiety-depression scale (HAD)</measure>
    <time_frame>9 months</time_frame>
    <description>To analyze the efficacy of the active product, in patients with CFS / ME vs. placebo in the improvement of anxiety-depressive symptomatology, through the hospital anxiety-depression scale (HAD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (SF-36)</measure>
    <time_frame>9 months</time_frame>
    <description>To evaluate the efficacy of the active product, in patients with CFS / ME vs. placebo in the improvement of the quality of life, through the SF-36 questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Fatigue Syndrome</condition>
  <condition>Myalgic Encephalomyelitis</condition>
  <arm_group>
    <arm_group_label>ImmunoVita®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>250 mg Yeast beta-glucan + 3.75 microg Vitamin D3 + 1.05 mg Vitamin B6 + 7.5 mg zinc)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>473,2 mg microcristalline cellulose + 0,06 mg Brown Oxide dye + 0,27 mg yellow A oxide dye</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Active</intervention_name>
    <description>Take 4 capsules daily (2 capsules on an empty stomach + 2 capsules 30 minutes before dinner).</description>
    <arm_group_label>ImmunoVita®</arm_group_label>
    <other_name>ImmunoVita®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Take 4 capsules daily (2 capsules on an empty stomach + 2 capsules 30 minutes before dinner).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients of both sexes, between 18-65 years.&#xD;
&#xD;
          -  Patients with a BMI ≤ 25.&#xD;
&#xD;
          -  Patients diagnosed with Chronic Fatigue Syndrome according to diagnostic criteria of&#xD;
             1994 CDC / Fukuda and 2003 Canadian criteria from the University of Central&#xD;
             Sensitization Syndrome (Vall d'Hebron University Hospital, Barcelona).&#xD;
&#xD;
          -  Patients who freely grant written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are participating in another clinical trial of the same or different&#xD;
             nature in the last 30 days prior to inclusion.&#xD;
&#xD;
          -  Any subject that, in the opinion of the investigator, is not able to follow the&#xD;
             instructions or make a good completion of the treatment.&#xD;
&#xD;
          -  Subjects who do not grant written informed consent to participate in the study.&#xD;
&#xD;
          -  Patients who are receiving any of the prohibited drugs or products and that the&#xD;
             withdrawal of the drugs / products not allowed in the study is expected to pose a&#xD;
             relevant problem.&#xD;
&#xD;
          -  Pregnant women and / or during breastfeeding periods.&#xD;
&#xD;
          -  Patients under treatment with oral anticoagulants.&#xD;
&#xD;
          -  Patient with any type of immunosuppression.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Alegre, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Vall d´Hebron</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jesús Castro-Marrero, PhD</last_name>
    <phone>+ 34 93 4893000</phone>
    <phone_ext>3753</phone_ext>
    <email>jesus.castro@vhir.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aleix P. Cuenca, MD</last_name>
    <phone>+34 658089458</phone>
    <email>apellejero@vitae.es</email>
  </overall_contact_backup>
  <reference>
    <citation>Castro-Marrero J, Sáez-Francàs N, Santillo D, Alegre J. Treatment and management of chronic fatigue syndrome/myalgic encephalomyelitis: all roads lead to Rome. Br J Pharmacol. 2017 Mar;174(5):345-369. doi: 10.1111/bph.13702. Epub 2017 Feb 1. Review.</citation>
    <PMID>28052319</PMID>
  </reference>
  <reference>
    <citation>Barbado Hernández FJ, Gómez Cerezo J, López Rodríguez M, Vázquez Rodríguez JJ. [The chronic fatigue syndrome and its diagnosis in internal medicine]. An Med Interna. 2006 May;23(5):238-44. Review. Spanish.</citation>
    <PMID>16817704</PMID>
  </reference>
  <reference>
    <citation>Akramiene D, Kondrotas A, Didziapetriene J, Kevelaitis E. Effects of beta-glucans on the immune system. Medicina (Kaunas). 2007;43(8):597-606. Review.</citation>
    <PMID>17895634</PMID>
  </reference>
  <reference>
    <citation>El Khoury D, Cuda C, Luhovyy BL, Anderson GH. Beta glucan: health benefits in obesity and metabolic syndrome. J Nutr Metab. 2012;2012:851362. doi: 10.1155/2012/851362. Epub 2011 Dec 11.</citation>
    <PMID>22187640</PMID>
  </reference>
  <reference>
    <citation>Ganda Mall JP, Casado-Bedmar M, Winberg ME, Brummer RJ, Schoultz I, Keita ÅV. A β-Glucan-Based Dietary Fiber Reduces Mast Cell-Induced Hyperpermeability in Ileum From Patients With Crohn's Disease and Control Subjects. Inflamm Bowel Dis. 2017 Dec 19;24(1):166-178. doi: 10.1093/ibd/izx002. Erratum in: Inflamm Bowel Dis. 2018 Oct 12;24(11):2476.</citation>
    <PMID>29272475</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 4, 2020</study_first_submitted>
  <study_first_submitted_qc>March 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2020</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fatigue Syndrome</keyword>
  <keyword>Encephalomyelitis</keyword>
  <keyword>Fibromyalgia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue Syndrome, Chronic</mesh_term>
    <mesh_term>Encephalomyelitis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

